Chenghui Li

High Impact

Associate Professor

University of Arkansas for Medical Sciences

faculty

Pharmacy Practice, College of Pharmacy

cli@uams.edu

23 h-index 177 pubs 1,938 cited

Is this your profile? Verify and claim your profile

Biography and Research Information

OverviewAI-generated summary

Chenghui Li's research investigates the pharmacological effects and toxicity of various therapeutic agents, with a particular focus on immune checkpoint inhibitors and their associated cardiotoxicity. Li also studies the real-world survival outcomes for patients receiving first-line immune checkpoint inhibitor treatment or chemotherapy, particularly in older individuals with non-small-cell lung cancer and synchronous brain metastases. Further research areas include examining rural-urban disparities in patient care experiences among prostate cancer survivors and investigating the molecular mechanisms of viral infections, such as Japanese encephalitis virus, in both animal models and mosquito populations.

Li's work extends to the analysis of signaling pathways involved in cancer progression, including the IL6/STAT3 pathway in gastric cancer. Additionally, Li has explored the association between discontinuing chronic opioid therapy and the subsequent diagnosis of substance use disorders, accidents, self-inflicted injuries, and drug overdoses. This body of work has resulted in 177 publications and an h-index of 23, with 1,938 total citations, designating Li as a highly cited researcher. Key collaborators include Bradley C. Martin, Jacob T. Painter, Corey J. Hayes, and Jonathan Laryea, all from the University of Arkansas for Medical Sciences, with whom Li has co-authored multiple publications.

Metrics

  • h-index: 23
  • Publications: 177
  • Citations: 1,938

Selected Publications

  • Impact of a minimally invasive approach for colon cancer surgery on outcomes in patients with functional limitations (2025) DOI
  • Colorectal cancer survival disparities in persistent poverty areas (2025) DOI
  • Bias in Prediction Models to Identify Patients With Colorectal Cancer at High Risk for Readmission After Resection (2024) DOI
  • Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases (2024) DOI
  • Opioid therapy trajectories of patients with chronic non-cancer pain over 1 year of follow-up after initiation of short-acting opioid formulations (2024) DOI
  • Maximizing Readmission Reduction in Colon Cancer Patients (2023) DOI
  • Food Insecurity and Health Outcomes of Children With Intellectual and Developmental Disabilities in the United States (2023) DOI
  • Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non–Small-Cell Lung Cancer and Synchronous Brain Metastases (2023) DOI
  • Differences in racial/ethnic disparities in patient care experiences between prostate cancer survivors and males without cancer: A SEER-CAHPS study (2023) DOI
  • Prior Pharmacy Work Experience as a Predictor of Clinical and Didactic Performance for Admissions Committees (2023) DOI
  • Rural–Urban Disparities in Patient Care Experiences among Prostate Cancer Survivors: A SEER-CAHPS Study (2023) DOI
  • The use of gabapentinoids and opioids and risk of developing opioid-induced respiratory depression among older breast cancer survivors with neuropathic pain (2023) DOI
  • Consistency Between State's Cancer Registry and All-Payer Claims Database in Documented Radiation Therapy Among Patients Who Received Breast Conservative Surgery (2023) DOI
  • Healthcare costs and utilization associated with pain among breast cancer survivors: a propensity score matched cohort study using SEER-Medicare data (2022) DOI
  • Racial/Ethnic Disparities in Patient Care Experiences among Prostate Cancer Survivors: A SEER-CAHPS Study (2022) DOI

Grants & Funding

  • GLP-1 Based Therapies on Lymphedema in Overweight or Obese Breast Cancer Patients State of Arkansas - Pass Through: Arkansas Breast Cancer Research Program Principal Investigator
  • The Impact of Arkansas Medicaid Coverage Expansion and Change in Prior Authorization Procedure on Utilization of Tobacco Cessation Treatment among Ark Robert Wood Johnson Foundation Principal Investigator
  • Assessment of HER2-Low Testing Methods, Treatment Patterns and Clinical Outcomes in Advanced Breast Cancer: A Multicenter Chart Review Study AstraZeneca - Pass Through: University of Utah Principal Investigator
  • No FP attached University of Utah Principal Investigator
  • Affordable care act on racial disparity in endocrine therapy use among females with early stage hormone receptor positive breast cancer American Cancer Society, Inc. Principal Investigator
  • Assessment of HER2-Low Testing Methods, Treatment Patterns and Clinical Outcomes in Advanced Breast Cancer: A Multicenter Chart Review Study AstraZeneca - Pass Through: University of Utah Principal Investigator
  • No FP attached University of Utah Principal Investigator
  • Ambulatory Resource Utilization for Gout and Gouty Arthritis Flares NOVARTIS Pharmaceuticals Corporation Principal Investigator

Collaborators

Researchers in the database who share publications

Similar Researchers

Based on overlapping research topics